Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RNArt
New York, New York, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
RNArt is a biotechnology company specializing in the design and development of circular RNA (circRNA) therapeutics. Founded by RNA biology pioneer Dr. Thomas Tuschl, the company focuses on leveraging the unique structural properties of circularized RNA to improve the stability and translation efficiency of RNA-based medicines. By overcoming the limitations of traditional linear mRNA, such as rapid degradation and immunogenicity, RNArt aims to create next-generation vaccines and protein replacement therapies. In early 2024, the company was acquired by BioNTech to integrate its proprietary circRNA technology into BioNTech's global portfolio of immunotherapy and infectious disease programs.
- Therapeutic areas
- Infectious DiseasesOncology
- Modalities
- RNA therapymRNA-based drugs
- Industry
- Biotech
02
Partnerships
BioNTech
Beyond the preview
Go deeper on RNArt.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RNArt.